NCT07600736 ABS-1230 Epilepsy Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Turn a newly registered trial into a decision-ready clinical landscape. This report examines NCT07600736 using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, with Drug & Asset MCP and Company & Deal Intelligence MCP used as the companion asset and sponsor enrichment workflow. Explore PatSnap MCP Servers to reproduce the research sequence inside an AI workflow.
MCP evidence snapshot: 23 July 2026. Trial records, recruitment status and projected dates can change after the snapshot and should be rechecked before operational decisions.
Why NCT07600736 is a hot trial to watch
Epilepsy is being segmented by mechanism, treatment setting, geography and endpoint architecture. NCT07600736 is notable because it evaluates ABS-1230 in a Phase 2 design sponsored by Actio Biosciences, Inc.. The main development question is whether the protocol can translate its rationale into a clinically interpretable and operationally credible readout.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | NCT07600736 |
| Official title | A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of ABS-1230 in Pediatric Participants With KCNT1-related Epilepsy (KYRON) |
| Phase / status | Phase 2 / Recruiting |
| Intervention | ABS-1230 |
| Sponsor | Actio Biosciences, Inc. |
| Geography | United States |
| Enrollment | [object Object] |
| Primary endpoint | Part 1: Safety and tolerability of ABS-1230 (incidence and severity of adverse events) |
| Endpoint time frame | Measured from Day 1 to End of Study or Early Termination (up to 12 weeks) |
| Primary completion / readout proxy | [object Object] |
Protocol design and endpoint interpretation
This trial will evaluate the safety, tolerability, pharmacokinetics, and clinical activity of ABS-1230 compared with placebo in participants with KCNT1-related epilepsy
Allocation is Randomized, masking is Triple, and the intervention model is Parallel Assignment. Planned enrollment of [object Object] participants across United States shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.
- Part 1: Safety and tolerability of ABS-1230 (incidence and severity of adverse events) (Measured from Day 1 to End of Study or Early Termination (up to 12 weeks)) — Safety and tolerability of ABS-1230 by determining the incidence and severity of treatment emergent adverse events
- Part 2: Efficacy of ABS-1230 (Measured from Day 1 to End of Study or Early Termination (up to 12 weeks)) — Percentage change from baseline in countable motor seizures (normalized per 28 days) as recorded in the seizure diary
- Part 3: Safety and tolerability of ABS-1230 (incidence and severity of adverse events) (Measured from Day 1 of Part 3 to End of Study or Early Termination (up to 1 year)) — Safety and tolerability of ABS-1230 by determining the incidence and severity of treatment emergent adverse events
Readout outlook and evidence gap
The current protocol points to [object Object] as the best available readout proxy. Because this is an active or newly posted study, a trial-specific result citation is not included until a normalized clinical-trial-result record becomes available. That gap is itself operationally important: teams should monitor first result indexing, conference abstracts, protocol amendments and changes to the primary-completion date.
Build a living trial monitor: connect to PatSnap MCP Servers and track recruitment, endpoint revisions, projected readouts and new result records without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset MCP profile: ABS-1230 is indexed as Small molecule drug, with target KCa4.1, mechanism KCa4.1 inhibitors, and global highest development status Phase 2.
Company & Deal Intelligence MCP profile: Actio Biosciences, Inc. is resolved to a normalized organization record in SAN DIEGO COUNTY, United States. The organization workflow adds identity, location, portfolio and partnering context where available.
The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
- Comparator relevance: evidence against the most decision-relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.
What to monitor next
Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter the probability of success before a headline data release.
Bottom line
NCT07600736 provides a focused lens on Epilepsy development. Its value will be determined by whether ABS-1230 can convert the current Phase 2 design into evidence that is clinically meaningful, operationally credible and differentiated from competing programs.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
